AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26714784 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) by inflating an upper extremity blood-pressure cuff for 3 x 5 min to 200 mmHg
Number of subjects: 24
Study 26714784 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 24
Study 23514036 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme Iron Polypeptide (HIP) 11 mg orally 3 times per day
Number of subjects: 40
Study 23514036 — intervention group
Group type: COMPARATOR
Intervention: IV iron sucrose 200 mg monthly for 6 months
Number of subjects: 40
Study 18158618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing with high resting lower paraspinal muscle tension
Number of subjects: 97
Study 18158618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing with low cardiovascular reactivity (SBP, DBP, HR)
Number of subjects: 97
Study 12511176 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 160
Study 12511176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 160
Study 12511176 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone plus Acamprosate
Number of subjects: 160
Study 12511176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10985268 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitals implementing measurement activities or systematic improvements
Number of subjects: 117
Study 10985268 — intervention group
Group type: COMPARATOR
Intervention: All other hospitals in the state (control group)
Number of subjects: 117
Study 8803505 — intervention group
Group type: EXPERIMENTAL
Intervention: Velodrome test
Number of subjects: 12
Study 8803505 — intervention group
Group type: COMPARATOR
Intervention: Laboratory test
Number of subjects: 12
Study 8803505 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2max)
Number of subjects: 12
Study 1738009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group taught to reduce dietary fat intake to 15% of total calories from a baseline average of 35% of calories.
Number of subjects: 507
Study 1738009 — intervention group
Group type: COMPARATOR
Intervention: Control group taught the principles of balanced nutrition without counseling to change fat intake.
Number of subjects: 507
Study 1738009 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified procedure for entry with subjects first taught procedures before consent and randomization.
Number of subjects: 507
Study 6436182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefroxadine 250 mg q.i.d. for ten days
Number of subjects: 64
Study 6436182 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 500 mg q.i.d. for ten days
Number of subjects: 64
Study 6436182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefroxadine
Number of subjects: 64
Study 6436182 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 64
Study 31469303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide combined with basal insulin
Number of subjects: 0
Study 31469303 — intervention group
Group type: COMPARATOR
Intervention: Basal-plus
Number of subjects: 0
Study 31469303 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus
Number of subjects: 0
Study 29271022 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation (120 mg elemental iron, 3 mg folic acid, 100 mg vitamin C)
Number of subjects: 292
Study 29271022 — intervention group
Group type: COMPARATOR
Intervention: Daily supplementation (60 mg elemental iron, 1 mg folic acid, 100 mg vitamin C)
Number of subjects: 292
Study 27297850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 0
Study 27297850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25502755 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide methylated DNA immunoprecipitation sequencing (MeDIP-seq)
Number of subjects: 54
Study 25502755 — intervention group
Group type: COMPARATOR
Intervention: Replication in 221 controls
Number of subjects: 54
Study 25502755 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated genomics and epigenomics approach
Number of subjects: 54
Study 25502755 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of T2D-discordant twins
Number of subjects: 54
Study 22325157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g/d BSP (group A)
Number of subjects: 81
Study 22325157 — intervention group
Group type: EXPERIMENTAL
Intervention: 5g/d BSP (group B)
Number of subjects: 81
Study 22325157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 81
Study 20362977 — intervention group
Group type: EXPERIMENTAL
Intervention: High ruminators
Number of subjects: 242
Study 20362977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ruminators
Number of subjects: 242
Study 20362977 — intervention group
Group type: COMPARATOR
Intervention: Worry (high and low)
Number of subjects: 242
Study 18827074 — intervention group
Group type: EXPERIMENTAL
Intervention: XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily)
Number of subjects: 136
Study 18827074 — intervention group
Group type: COMPARATOR
Intervention: XP13512 extended-release (equimolar dose compared with 600 mg gabapentin)
Number of subjects: 136
Study 18827074 — intervention group
Group type: COMPARATOR
Intervention: Oral gabapentin (up to 1200 mg)
Number of subjects: 136
Study 16114985 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific vaccine (3 weekly injections of irradiated tumor cells)
Number of subjects: 156
Study 12925626 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted implantation
Number of subjects: 154
Study 12925626 — intervention group
Group type: COMPARATOR
Intervention: Manual implantation
Number of subjects: 154
Study 10388499 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 90
Study 10388499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8905030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Progenitor Cells (BMPC)
Number of subjects: 570
Study 8905030 — intervention group
Group type: EXPERIMENTAL
Intervention: BMPC & Peripheral Blood Progenitor Cells (PBPC)
Number of subjects: 570
Study 8905030 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Progenitor Cells (PBPC) alone
Number of subjects: 570
Study 2002134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 57
Study 2002134 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 57
Study 2002134 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 57
Study 6139119 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 12 mg
Number of subjects: 0
Study 6139119 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 27 mg
Number of subjects: 0
Study 29963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 108
Study 29963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 108
Study 29963892 — intervention group
Group type: COMPARATOR
Intervention: CPT or PE (combined results)
Number of subjects: 108
Study 30545596 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowable gas-filled intragastric balloon system plus lifestyle therapy
Number of subjects: 387
Study 30545596 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle therapy alone
Number of subjects: 387
Study 26821696 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 0.05 µg kg(‐1) min(‐1) infusion
Number of subjects: 100
Study 26821696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 100
Study 24613294 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (6 soft-gel capsules of fish oil daily for 4 months)
Number of subjects: 45
Study 24613294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin oil capsules)
Number of subjects: 45
Study 24613294 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 45
Study 24613294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22273457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary eptifibatide bolus only (Group A, n=67)
Number of subjects: 155
Study 22273457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus and continuous intravenous infusion of eptifibatide (Group B, n=88)
Number of subjects: 155
Study 19798503 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB-monotherapy
Number of subjects: 1351
Study 19798503 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB add-on
Number of subjects: 1351
Study 19798503 — intervention group
Group type: COMPARATOR
Intervention: Non-PGB drugs
Number of subjects: 1351
Study 17123615 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 210
Study 15669555 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (HRT) with 2 mg estradiol valerate and 2 mg dienogest
Number of subjects: 129
Study 15669555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 12499617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil cocktail (24 mg nicorandil, 5 mg nitroglycerin, 10,000 U heparin)
Number of subjects: 61
Study 12499617 — intervention group
Group type: COMPARATOR
Intervention: Verapamil cocktail (10 mg verapamil, 5 mg nitroglycerin, 10,000 U heparin)
Number of subjects: 61
Study 10752844 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 0
Study 10752844 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study 8991321 — intervention group
Group type: EXPERIMENTAL
Intervention: narrative elaboration intervention
Number of subjects: 132
Study 8991321 — intervention group
Group type: EXPERIMENTAL
Intervention: instruction-based intervention
Number of subjects: 132
Study 8991321 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 132
Study 1479795 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg tyrosine per kg body weight per day
Number of subjects: 8
Study 1479795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3881838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 48
Study 3881838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 48
Study 3881838 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (in patients where it failed)
Number of subjects: 48
Study 3881838 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (in patients where it failed)
Number of subjects: 48
Study 30291682 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of cytidine (2%, 3%, and 4% w/w)
Number of subjects: 0
Study 30291682 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control formulation
Number of subjects: 0
Study 29609720 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline bolus of 22 mL/kg body weight
Number of subjects: 21
Study 29609720 — intervention group
Group type: COMPARATOR
Intervention: Minimum rate saline infusion (control)
Number of subjects: 21
Study 27442997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0
Study 27442997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24953909 — intervention group
Group type: EXPERIMENTAL
Intervention: Self etch adhesive (adhe SE one Ivoclar)
Number of subjects: 70
Study 24953909 — intervention group
Group type: COMPARATOR
Intervention: Total etch adhesive (Eco‐Etch Ivoclar)
Number of subjects: 70
Study 22383098 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral sildenafil
Number of subjects: 14
Study 22383098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19747047 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of apolipoprotein E epsilon4 allele
Number of subjects: 46
Study 19747047 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP-targeted therapy based on the Lund concept
Number of subjects: 46
Study 19747047 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS and ICP measurements
Number of subjects: 46
Study 17410948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint Floss Pick
Number of subjects: 26
Study 17410948 — intervention group
Group type: COMPARATOR
Intervention: Standard Rolled Floss
Number of subjects: 26
Study 15694110 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg/24 h (Femseven)
Number of subjects: 19
Study 15694110 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 19
Study 12400528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent meningococcal polysaccharide vaccine conjugated to diphtheria at 1, 4, and 10 microg/ml dosages
Number of subjects: 30
Study 12400528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent meningococcal polysaccharide vaccine conjugated to diphtheria at 4 microg/ml
Number of subjects: 30
Study 11783185 — intervention group
Group type: EXPERIMENTAL
Intervention: Runing Granule (RNG)
Number of subjects: 187
Study 11783185 — intervention group
Group type: COMPARATOR
Intervention: Tabellae Tamoxifen (Control)
Number of subjects: 187
Study 7825538 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-fat diet (enzymatically modified palm oil)
Number of subjects: 60
Study 7825538 — intervention group
Group type: COMPARATOR
Intervention: Palm oil diet
Number of subjects: 60
Study 2192497 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical compliance
Number of subjects: 30
Study 2192497 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of ventilation
Number of subjects: 30
Study 2192497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation pressure
Number of subjects: 30
Study 31488289 — intervention group
Group type: EXPERIMENTAL
Intervention: T+S (0.5 mg testosterone and 50 mg sildenafil) under fed conditions
Number of subjects: 18
Study 31488289 — intervention group
Group type: COMPARATOR
Intervention: T+S (0.5 mg testosterone and 50 mg sildenafil) under fasted conditions
Number of subjects: 18
Study 29084632 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 833
Study 29084632 — intervention group
Group type: COMPARATOR
Intervention: No Brief Intervention (no BI)
Number of subjects: 833
Study 25682286 — intervention group
Group type: EXPERIMENTAL
Intervention: THP group (docetaxel, THP, cyclophosphamide)
Number of subjects: 48
Study 25682286 — intervention group
Group type: COMPARATOR
Intervention: EPI group (docetaxel, EPI, cyclophosphamide)
Number of subjects: 48
Study 25682286 — intervention group
Group type: EXPERIMENTAL
Intervention: THP group
Number of subjects: 48
Study 25682286 — intervention group
Group type: COMPARATOR
Intervention: EPI group
Number of subjects: 48
Study 23772723 — intervention group
Group type: EXPERIMENTAL
Intervention: NP comanagement
Number of subjects: 485
Study 23772723 — intervention group
Group type: COMPARATOR
Intervention: PCP care alone
Number of subjects: 485
Study 21613745 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 45
Study 21613745 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 45
Study 19419443 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive intra-muscular neridronate (12.5 mg injection/week for 3 months)
Number of subjects: 60
Study 19419443 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment (PT) only
Number of subjects: 60
Study 16393441 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.2 mg)
Number of subjects: 46
Study 16393441 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine tablets (5 mg)
Number of subjects: 46
Study 16393441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15280773 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype C env (C-env)
Number of subjects: 253
Study 15280773 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 subtype A env (A-env)
Number of subjects: 253
Study 15280773 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 subtype D env (D-env)
Number of subjects: 253
Study 15280773 — intervention group
Group type: COMPARATOR
Intervention: Combined subtypes A env and D env
Number of subjects: 253
Study 11226744 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg MEL
Number of subjects: 0
Study 11226744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9215017 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronidase 300 iu ml‐1
Number of subjects: 200
Study 9215017 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronidase 50 iu ml‐1
Number of subjects: 200
Study 7535064 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 165
Study 7535064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 165
Study 7535064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 7535064 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (high-dose, low-dose, placebo)
Number of subjects: 165
Study 7535064 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high and low doses)
Number of subjects: 165
Study 3555584 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg + HCTZ 12.5 mg (25/12.5)
Number of subjects: 111
Study 3555584 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + HCTZ 25 mg (50/25)
Number of subjects: 111
Study 3555584 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 100 mg + HCTZ 50 mg (100/50)
Number of subjects: 111
Study 3555584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 30145148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (FU)/bevacizumab (Bev)
Number of subjects: 471
Study 30145148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev)
Number of subjects: 471
Study 30145148 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 471
Study 30145148 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 471
Study 30145148 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutation
Number of subjects: 471
Study 30145148 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS mutation
Number of subjects: 471
Study 26480205 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered psychotherapy (T-P)
Number of subjects: 221
Study 26480205 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered social rhythm therapy (T-SRT)
Number of subjects: 221
Study 26480205 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered intensive clinical management (T-ICM)
Number of subjects: 221
Study 26480205 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 221
Study 24286379 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (3 months)
Number of subjects: 46
Study 24286379 — intervention group
Group type: COMPARATOR
Intervention: Non-quitters
Number of subjects: 46
Study 22438325 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced transfusions
Number of subjects: 489
Study 22438325 — intervention group
Group type: COMPARATOR
Intervention: Nonleukoreduced transfusions
Number of subjects: 489
Study 20434604 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) system for 3 months, activating during walking for 6 to 8 hours/day, 7 days/week, plus walking 1 hour/day, 6 days/week
Number of subjects: 28
Study 20434604 — intervention group
Group type: COMPARATOR
Intervention: Walking 1 hour/day, 6 days/week without FES
Number of subjects: 28
Study 18164460 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 18164460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical interventions
Number of subjects: 0
Study 15871591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 12952838 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 36
Study 12952838 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36
Study 9892124 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified flexible suture implant
Number of subjects: 2
Study 9892124 — intervention group
Group type: COMPARATOR
Intervention: Tricortical screw
Number of subjects: 2
Study 9892124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions at 5.0 cm
Number of subjects: 2
Study 9892124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions at 2.0 cm
Number of subjects: 2
Study 8545491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity ergometer test (LE test)
Number of subjects: 15
Study 8545491 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-cranking ergometer test (AC test)
Number of subjects: 15
Study 1839585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d.)
Number of subjects: 60
Study 1839585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6356556 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin instillation at 1 week intervals followed by 6 instillations at 2 weeks intervals and then 8 instillations at 4 weeks intervals.
Number of subjects: 411
Study 6356556 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin instillation at intervals of 1, 2, and 4 weeks (first study).
Number of subjects: 411
Study 31866929 — intervention group
Group type: EXPERIMENTAL
Intervention: eCBT‐I (automated Internet‐delivered cognitive behavioral therapy for insomnia)
Number of subjects: 46
Study 31866929 — intervention group
Group type: EXPERIMENTAL
Intervention: eCBT‐I
Number of subjects: 46
Study 31866929 — intervention group
Group type: COMPARATOR
Intervention: mPT (minimal psychoeducation therapy)
Number of subjects: 46
Study 31866929 — intervention group
Group type: COMPARATOR
Intervention: eCBT‐I and mPT
Number of subjects: 46
Study 28460127 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS plus a brief cognitive intervention (BCI)
Number of subjects: 79
Study 28460127 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS plus pain education
Number of subjects: 79